As Peptides Go Mainstream, CeliaRx Aims To Cut Through The Noise

Just a few years ago, peptides were largely confined to the niche realms of biohackers, longevity enthusiasts, and a small circle of functional medicine practitioners. As consumers increasingly seek proactive approaches to health and longevity, however, the category has rapidly moved from the fringes of wellness into the mainstream, and peptides have emerged as one of the industry’s fastest-growing sectors, driving conversations around recovery, metabolic health, skin rejuvenation, hormone optimization, and healthy aging.

Koehl Robinson has watched that evolution happen in real time. As interest around longevity, recovery, and proactive health optimization gained momentum, she saw consumers struggling to make sense of a rapidly expanding and often confusing peptide market. Sensing both a growing demand and a gap in trusted guidance, the entrepreneur and longevity advocate created CeliaRx, a telehealth platform designed to help bring physician-guided peptide care to a broader audience.

The company offers physician-guided peptide protocols through a streamlined digital platform, allowing patients to complete an intake, consult with licensed providers, receive personalized recommendations, and have treatments delivered directly to their homes. The larger goal, Robinson says, is to remove some of the confusion surrounding a category that has exploded in popularity but remains poorly understood by many consumers. “We’re seeing a broader shift in healthcare where people are no longer satisfied with waiting until they’re sick to take action,” the founder explains. “Consumers want solutions that help them optimize performance, recovery, energy, and long-term health proactively.”

That change has helped propel peptides into the mainstream wellness conversation. Unlike traditional pharmaceuticals that often focus on treating symptoms, peptides are short chains of amino acids that act as signaling molecules within the body, influencing processes such as tissue repair, metabolism, immune response, and recovery.

Of course, the surge in interest has also created significant confusion. “One of the biggest misconceptions is that all peptides are experimental or unproven,” Robinson says. “Another misconception is that peptides are a shortcut or magic solution. They’re not. They’re tools that can support specific biological functions when used appropriately under medical supervision.”

And for Robinson, the business of peptides is deeply personal. The inspiration for CeliaRx came to her after navigating serious health challenges, including severe parasitic infections, chronic inflammation, long COVID complications, immune dysfunction, and bilateral rotator cuff injuries. After what she describes as years of unsuccessful treatments, peptide therapy became a turning point. “When I discovered peptides, what stood out was their ability to support the body’s own repair and regulatory mechanisms,” she says. “They truly changed my life.”

That experience ultimately shaped the company’s philosophy: helping consumers access personalized, medically supervised peptide care without having to navigate what Robinson sees as a disjointed and often opaque marketplace. “The market was and is fragmented,” she says. “Consumers are navigating a confusing landscape of online information, questionable suppliers, and disconnected healthcare experiences.”

To address that, CeliaRx places a heavy emphasis on physician oversight, education, and personalization. Rather than recommending the same protocol for every patient, the company focuses on individualized plans based on health history, goals, and ongoing monitoring. “Human biology is incredibly complex,” Robinson notes. “So, two people with similar goals can have completely different underlying physiology, lifestyle factors, and health histories.”

That personalized approach extends to one of the company’s core concepts: peptide “stacking,” or combining multiple peptides to support interconnected biological systems simultaneously. “The body doesn’t operate in isolated pathways–sleep affects recovery, recovery affects metabolism, metabolism affects energy, and so on,” Robinson explains. “So, rather than targeting a single outcome in isolation, we’re looking at the broader health picture.”

The focus on data is another reflection of where the broader wellness industry appears to be heading. Consumers are increasingly turning to biomarker testing, wearable technology, and personalized health metrics to guide decision-making, and Robinson believes peptide therapy will become more and more integrated with those tools. “We’re entering an era where people want objective insights, not guesswork,” she says.

With that in mind, CeliaRx plans to launch what it calls “Celia Intelligence,” a platform designed to help users track biological data and use that information to inform peptide selection, dosing, and cycling protocols, later this year. The company is also investing in delivery innovation. Among its initiatives is Rapid Ion Technology, a patented nasal delivery system designed to improve peptide absorption and bioavailability compared to traditional nasal sprays.

As with so many rapidly growing wellness categories, though, enthusiasm for peptides has still outpaced public understanding. The challenge facing companies like CeliaRx isn’t simply making peptides more accessible; it’s helping consumers separate evidence-based applications from marketing hype.

Robinson acknowledges that tension. “Innovation is exciting, but responsibility has to come first,” she says. “Our role isn’t to chase trends. It’s to help people make informed decisions based on credible information and sound medical judgment.”

Whether peptides ultimately follow the trajectory of supplements, wearable health technology, or another wellness trend entirely remains to be seen, but the CeliaRx founder believes the category is moving toward broader adoption. “What we’re seeing today reminds me of the early days of fitness tracking and personalized nutrition,” she says. “Technologies that were once available only to a small group are becoming more accessible to the broader population.”

For Robinson, the larger goal isn’t to extend lifespan at all costs per se, but rather to improve overall quality of life and help people stay healthier, longer. “I hope we help shift the conversation from managing decline to maximizing potential,” she says. “Our goal is quality of life in the present moment and a future where illness seems distant—not necessarily living forever.” If the growing interest in longevity is any indication, many consumers seem to be thinking the same way.